These tumors can be either HER2+ or HER2−, with HER2 expression indicating poorer prognosis compared with luminal A. The overexpression of HER2, in the absence of other hormone receptors, characterizes another tumor subtype that is more aggressive than either the luminal A or B subtypes. Here, ERBB2 is linked to neoplasm.